Protagonist Therapeutics Inc (NASDAQ: PTGX) kicked off on Tuesday, down -4.65% from the previous trading day, before settling in for the closing price of $43.26. Over the past 52 weeks, PTGX has traded in a range of $18.07-$48.89.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 2462.45% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 284.28%. With a float of $56.30 million, this company’s outstanding shares have now reached $59.52 million.
In an organization with 112 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 99.21%, operating margin of 46.05%, and the pretax margin is 53.45%.
Protagonist Therapeutics Inc (PTGX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Protagonist Therapeutics Inc is 5.54%, while institutional ownership is 100.44%. The most recent insider transaction that took place on Nov 27 ’24, was worth 1,162,280. In this transaction Chief Medical Officer of this company sold 26,000 shares at a rate of $44.70, taking the stock ownership to the 46,444 shares. Before that another transaction happened on Nov 26 ’24, when Company’s Chief Medical Officer sold 5,529 for $45.60, making the entire transaction worth $252,122. This insider now owns 46,444 shares in total.
Protagonist Therapeutics Inc (PTGX) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported 0.44 earnings per share (EPS), higher than consensus estimate (set at -0.18) by 0.62. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 284.28% per share during the next fiscal year.
Protagonist Therapeutics Inc (NASDAQ: PTGX) Trading Performance Indicators
Take a look at Protagonist Therapeutics Inc’s (PTGX) current performance indicators. Last quarter, stock had a quick ratio of 10.70. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.59. Likewise, its price to free cash flow for the trailing twelve months is 10.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.67, a number that is poised to hit 0.31 in the next quarter and is forecasted to reach -1.40 in one year’s time.
Technical Analysis of Protagonist Therapeutics Inc (PTGX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.57 million. That was inferior than the volume of 0.75 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 56.46%. Additionally, its Average True Range was 2.44.
During the past 100 days, Protagonist Therapeutics Inc’s (PTGX) raw stochastic average was set at 53.39%, which indicates a significant increase from 53.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 63.73% in the past 14 days, which was higher than the 44.49% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $45.02, while its 200-day Moving Average is $36.38. However, in the short run, Protagonist Therapeutics Inc’s stock first resistance to watch stands at $42.83. Second resistance stands at $44.40. The third major resistance level sits at $45.32. If the price goes on to break the first support level at $40.34, it is likely to go to the next support level at $39.42. Assuming the price breaks the second support level, the third support level stands at $37.85.
Protagonist Therapeutics Inc (NASDAQ: PTGX) Key Stats
The company with the Market Capitalisation of 2.46 billion has total of 59,598K Shares Outstanding. Its annual sales at the moment are 60,000 K in contrast with the sum of -78,960 K annual income. Company’s last quarter sales were recorded 4,680 K and last quarter income was -33,210 K.
